Professor Puppet After Dark is brought to you by Adam & Eve. Go now to http://AdamAndEve.com and enter the Adam & Eve Coupon Code HANS to enjoy 50% OFF almost ANY item. Plus FREE Shipping , a FREE Special Gift, and FREE DVD’s.
Professor Hans and Penelope Lombard address an excellent viewer fan mail question from Lory this week. Will using a vibrator too often desensitize one from regular sex? There are two main results that you can get when using an electronic device or an artificial toy during solo play too often. One is that, essentially, you will get yourself numb and will crave for more powerful vibrations. Second, is that you will tend to train yourself to cum too quickly. We all know that women take a little longer to get off than men. Here’s another point though. It’s really good to have your prostate ejaculate maybe every couple of days but you just need to discipline yourself not to make it too often. Otherwise, you will lose your sexual appetite.
Abbott and the United States Department of Defense today announced a collaboration with the intent to develop portable blood tests to help evaluate potential concussions, also called mild traumatic brain injuries (TBIs). As part of a multi–phased approach, the tests would be developed for Abbott’s i–STAT® System, a handheld, diagnostic analyzer that is currently used for other point-of-care testing, including among military service members. Concussions are a significant health concern for military service members.1 With the development of new tests, physicians could use the information to positively impact the care of people with a suspected concussion.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7293951-abbott-u-s-department-of-defense-develop-portable-blood-tests-concussions/
NI (Nasdaq: NATI) today announced VirtualBench, an all-in-one instrument that integrates a mixed-signal oscilloscope, function generator, digital multimeter, programmable DC power supply and digital I/O. Users interact with VirtualBench through software applications that run on PCs or iPads. The device provides the most common functionality affordably and opens up new possibilities for how engineers can use benchtop instruments.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7230751-ni-reshapes-instrumentation-with-software-based-device-virtualbench
Learn how you can easily enable Emoji keyboard on your device!
Send amazing emoji pictures, unique emoticons, turn any word into emoji preset in a tap, and more! Get ultimate Emoji Emoticons Art iOS app https://itunes.apple.com/app/id593449409
How to enable Emoji 2 Keyboard on iOS 6
- Open Settings
- Go to General
- Scroll down and tap Keyboard
- Select Keyboards
- Tap Add New Keyboard
- Scroll down and select Emoji
- Emoji keyboard has been activated. Now you can use Emoji in Messages, Notes, Contacts, and more!
- Open the Messages app, for example
- Tap and hold the Globe at the bottom and then select Emoji
- Select the Emoji you like by tapping on it
What will it take for drivers to stop texting behind the wheel? Car-buying platform Edmunds.com believes that a gentle reminder from a loved one could do the trick.
Developers of the award-winning Edmunds app recently broke from their usual work to produce “DrivePromise by Edmunds,” a free app that allows Apple Watch and iPhone owners to make and keep a promise to focus on the road while driving. When the device detects that it is in a moving vehicle, it pops up an uploaded photo of a loved one along with a reminder to drive safely. The app keeps count of all of the user’s safe drives to share with friends and family.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7514851-drivepromise-edmunds-app/
LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today recognizes that more than one million people in the United States with drug-resistant epilepsy continue to be treated unsuccessfully with drugs, despite the proven effectiveness of non-drug treatment options. LivaNova’s VNS Therapy®, for example, is a medical device treatment specifically designed for people with drug-resistant epilepsy that is already used by more than 85,000 people around the world.
One in three people with epilepsy has the type that is not well controlled with drugs, called drug-resistant epilepsy. For those people, prescribing more medicine is usually not the most effective option. In fact, research shows that if you haven’t found seizure freedom after your first two drugs, there is a 95 percent chance that no drug or combination of drugs will result in seizure freedom.
“Despite what we know about drug-resistant epilepsy, the majority of people affected by this condition will continue to be prescribed additional medications instead of being evaluated for surgery or seen in a specialized epilepsy facility,” said Jason Richey, president of LivaNova’s U.S. Region and general manager of the Neuromodulation Business Franchise. “This treatment gap means over one million individuals in the U.S. with undertreated epilepsy remain at risk for dangerous side effects of continued seizures, including injury, depression, memory issues and death.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7966451-livanova-vns-therapy-epilepsy/
Can’t remember if you locked your front door or left your bedroom window open when you left your house? You’re not alone. Today, Pella® Corporation introduced its new Insynctive® technology app which provides homeowners self-monitored security via their mobile device. Now you can monitor the status of your Pella windows and doors and control motorized between-the-glass blinds and shades in a variety of Pella products, including Architect Series® collections, Designer Series® and entry doors. With the Pella Insynctive app, get real-time push notifications so you know the status of your windows and doors. This new Pella solution creates a way to achieve peace of mind for the 75 percent of Americans who have felt uncertain about whether or not they locked their doors.* Click here to learn more about the Pella Insynctive app works.
To view the multimedia release go to:
https://www.multivu.com/players/English/8334852-pella-windows-new-insynctive-app/
Continuing its commitment to bringing parents’ technology to the next generation of kids, VTech® today announces the availability of KidiBuzz™, an innovative new hand-held smart device for kids. With quality content and robust features similar to those found in parents’ smartphones, KidiBuzz lets kids play games, watch videos, listen to music, send text messages and more. Already one of the hottest toys for the holiday season, KidiBuzz has earned a place on the influential TTPM Most Wanted List.
“VTech has always strived to adapt adult technology for kids in a smart, engaging way that supports the way they play,” said William To, President, VTech Electronics North America. “KidiBuzz fills a need in the marketplace for kids growing up in the age of smartphones who want to mimic their parents, while addressing the concerns of parents who aren’t ready to commit to the expense and responsibility of a phone and plan.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8140758-vtech-kidibuzz-smart-device-for-kids/
ACCU-CHEK Aviva Expert offers people with diabetes a new and easy way to simplify complex calculations to deliver precise insulin dosing advice.
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the ACCU-CHEK® Aviva Expert system, the first and only blood glucose meter system with a built-in insulin calculator to be approved by the U.S. Food and Drug Administration (FDA), is now available by prescription. The device represents a significant advancement in blood glucose meter technology for people with diabetes who take multiple daily insulin injections. The meter’s integrated bolus calculator provides easy-to-use and reliable dose recommendations based on automated calculations, eliminating the need for manual dosing calculations and estimations.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7322751-roche-accu-chek-aviva-expert-blood-glucose-meter-now-available/
Following FDA approval of the AspireSR® generator for the VNS Therapy® system in June 2015, more than a thousand patients with drug-resistant epilepsy across the United States have received this new treatment option. Many of these patients are experiencing benefits which have positively impacted their lives – and are sharing their stories during Epilepsy Awareness Month with the hope of encouraging others to seek new treatments for drug-resistant epilepsy. Numerous hospitals nationwide have begun providing the AspireSR device to patients with drug-resistant epilepsy – a condition that affects as many as one-third of people with epilepsy, causing them to have seizures in spite of treatment with antiepileptic medications.
The VNS Therapy system is a minimally invasive option in which a medical device is placed under the skin in the upper chest area during an outpatient procedure. The device sends mild electrical pulses through the vagus nerve to areas of the brain known to be associated with seizures. The new AspireSR generator takes the VNS Therapy technology a step further – detecting relative heart-rate increases that are often associated with seizures in people with epilepsy and providing responsive stimulation in an attempt to stop and shorten seizures and improve recovery.
To view the multimedia release go to:
http://www.multivu.com/players/English/7651751-livanova-aspiresr-treatment/
Today, SunPower introduces the SunPower Equinox™ system, now available to U.S. homeowners. It is the first residential solar solution in the nation in which every major component has been designed and engineered by one company to work seamlessly together, delivering unbeatable power, long-term performance and curb appeal. With a typical SunPower Equinox installation, only the solar panels and a Smart Energy management device are visible, reflecting SunPower’s minimalist architectural approach at the system level.
The SunPower Equinox platform was engineered based on the company’s The Power of One™ philosophy, which drives innovation of preconfigured solutions that simplify solar for consumers. In 2010, SunPower introduced its Oasis® Power Plant, the world’s first fully integrated utility solar platform, which enables rapid, cost-effective construction of large-scale power plants, now with over 1.8 gigawatts deployed. In 2015, SunPower introduced the industry’s first fully integrated solar solution for commercial customers, the SunPower® Helix™ system, which can be installed on commercial rooftops more than 2.5 times faster than any commercial solar solution on the market. Now, the SunPower Equinox™ system brings The Power of One™ to homeowners.
To view the multimedia release go to:
http://www.multivu.com/players/English/7706152-sunpower-reinvents-home-solar-equinox/
Abbott announced today that the U.S. Food and Drug Administration has approved the company’s Absorb bioresorbable heart stent, making the first-of-its-kind medical device commercially available to treat people with coronary artery disease in the United States.
Absorb is the only fully dissolving stent approved for the treatment of coronary artery disease, which affects 15 million people in the United States and remains a leading cause of death worldwide, despite decades of therapeutic advances. While stents are traditionally made of metal, Abbott’s Absorb stent is made of a naturally dissolving material, similar to dissolving sutures. Absorb disappears completely in approximately three years, after it has done its job of keeping a clogged artery open and promoting healing of the treated artery segment. By contrast, metal stents are permanent implants that restrict vessel motion for the life of the person treated.
To view the multimedia release go to:
http://www.multivu.com/players/English/7826651-abbott-fda-approval-stent/
